Six cycles of R-CHOP-21 are not inferior to eight cycles for treatment of diffuse large B-cell lymphoma: a Nordic Lymphoma Group Population-based Study

被引：13
作者：
Wasterlid, T. [1 ,2 ]
Biccler, J. L. [3 ,4 ]
Brown, P. N. [5 ]
Bogsted, M. [4 ]
Enblad, G. [6 ]
Jorgensen, J. Meszaros [7 ]
Christensen, J. H. [8 ]
Wahlin, B. E. [9 ]
Smedby, K. E. [1 ]
El-Galaly, T. C. [3 ,4 ]
Jerkeman, M. [2 ]
机构：
[1] Karolinska Inst, Div Clin Epidemiol, Dept Med Solna, Stockholm, Sweden
[2] Lund Univ, Skane Univ Hosp, Dept Oncol, Lund, Sweden
[3] Aalborg Univ Hosp, Dept Hematol, Clin Canc Res Ctr, Aalborg, Denmark
[4] Aalborg Univ, Dept Clin Med, Aalborg, Denmark
[5] Rigshosp, Copenhagen Univ Hosp, Dept Hematol, Copenhagen, Denmark
[6] Uppsala Univ, Dept Immunol Genet & Pathol, Uppsala, Sweden
[7] Aarhus Univ Hosp, Dept Hematol, Aarhus, Denmark
[8] Odense Univ Hosp, Dept Hematol, Odense, Denmark
[9] Karolinska Inst, Div Hematol, Dept Med Huddinge, Stockholm, Sweden
来源：
ANNALS OF ONCOLOGY | 2018年 / 29卷 / 08期
关键词：
RITUXIMAB; CHOP;
D O I：
10.1093/annonc/mdy184
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：1882 / 1883
页数：3
相关论文
共 5 条
  • [1] Simplicity at the cost of predictive accuracy in diffuse large B-cell lymphoma: a critical assessment of the R-IPI, IPI, and NCCN-IPI
    Biccler, Jorne
    Eloranta, Sandra
    Brown, Peter de Nully
    Frederiksen, Henrik
    Jerkeman, Mats
    Smedby, Karin E.
    Bogsted, Martin
    El-Galaly, Tarec C.
    [J]. CANCER MEDICINE, 2018, 7 (01): : 114 - 122
  • [2] CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma.
    Coiffier, B
    Lepage, E
    Brière, J
    Herbrecht, R
    Tilly, H
    Bouabdallah, R
    Morel, P
    Van den Neste, E
    Salles, G
    Gaulard, P
    Reyes, F
    Gisselbrecht, C
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2002, 346 (04) : 235 - 242
  • [3] Rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisolone in patients with newly diagnosed diffuse large B-cell non-Hodgkin lymphoma: a phase 3 comparison of dose intensification with 14-day versus 21-day cycles
    Cunningham, David
    Hawkes, Eliza A.
    Jack, Andrew
    Qian, Wendi
    Smith, Paul
    Mouncey, Paul
    Pocock, Christopher
    Ardeshna, Kirit M.
    Radford, John A.
    McMillan, Andrew
    Davies, John
    Turner, Deborah
    Kruger, Anton
    Johnson, Peter
    Gambell, Joanna
    Linch, David
    [J]. LANCET, 2013, 381 (9880) : 1817 - 1826
  • [4] Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma
    Habermann, Thomas M.
    Weller, Edie A.
    Morrison, Vicki A.
    Gascoyne, Randy D.
    Cassileth, Peter A.
    Cohn, Jeffrey B.
    Dakhil, Shaker R.
    Woda, Bruce
    Fisher, Richard I.
    Peterson, Bruce A.
    Horning, Sandra J.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (19) : 3121 - 3127
  • [5] Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20+ B-cell lymphomas:: a randomised controlled trial (RICOVER-60)
    Pfreundschuh, Michael
    Schubert, Joerg
    Ziepert, Marita
    Schmits, Rudolf
    Mohren, Martin
    Lengfelder, Eva
    Reiser, Marcel
    Nickenig, Christina
    Clemens, Michael
    Peter, Norma
    Bokemeyer, Carsten
    Eimermacher, Hartmut
    Ho, Anthony
    Hoffmann, Martin
    Mertelsmann, Roland
    Truemper, Lorenz
    Balleisen, Leopold
    Liersch, Ruediger
    Metzner, Bernd
    Hartmann, Frank
    Glass, Bertram
    Poeschel, Viola
    Schmitz, Norbert
    Ruebe, Christian
    Feller, Alfred C.
    Loeffler, Markus
    [J]. LANCET ONCOLOGY, 2008, 9 (02) : 105 - 116
1